KYORIN and Lunatus Enter into Distribution Agreement for Lasvic Tablets in Nine Middle Eastern Countries1/5TDnetPDF(65KB)
[Summary]Consolidated Financial Results for the Six Months Ended September 30, 2025) [Japanese GAAP]11/7TDnetPDF(223KB)
Consolidated Financial Results for Second Quarter (Interim Period) of FY2025 - Supplementary Information11/7TDnetPDF(825KB)
KYORIN and Hinge Bio Enter into a Collaboration and License Agreement of HB2198 in Japan for SLE and other diseases10/1TDnetPDF(75KB)
Topline Results from Phase 3 Clinical Study of KRP-R120 for Interstitial Lung Disease9/16TDnetPDF(70KB)
Summary of Consolidated Financial Results(For the first quarter ended June 30, 2025) [Japanese GAAP]7/31TDnetPDF(233KB)
Consolidated Financial Results for First Quarter of FY2025 - Supplementary Information7/31TDnetPDF(607KB)